Shionogi & Co., Ltd. (SGIOF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Osaka, Japan. Der aktuelle CEO ist Isao Teshirogi.
SGIOF hat IPO-Datum 2018-02-28, 4,955 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $18.59B.
Shionogi & Co., Ltd. is a Japanese pharmaceutical company founded in 1878 and headquartered in Osaka that engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices. The company's marketed products include Fetroja for multidrug-resistant gram-negative bacterial infections, Xofluza for influenza, and Tivicay for HIV treatment. Shionogi maintains a substantial pipeline of drug candidates across multiple therapeutic areas including infectious diseases, oncology, central nervous system disorders, and rare diseases, with notable programs in obesity, depression, neuropathic pain, and COVID-19 treatments. The company also collaborates with leading academic institutions including Nagasaki University and the National Institute of Infectious Diseases on antimalarial drug development initiatives.
